# US 2021/0171929 A1 · Single base editing tools with precise accuracy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171929 A1
- Document ID: US20210171929A1
- Status: Published application
- Kind: A1
- Application number: 17/104,562
- Filed: 2020-11-25
- Published: 2021-06-10
- Earliest claimed: 2019-11-25
- Assignees: William Marsh Rice University
- Applicants: William Marsh Rice University
- Inventors: Xue GAO; Sangsin LEE; Ning DING
- Web page: https://patentgrep.com/patent/US20210171929A1

## CPC

- C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/907: {in mammalian cells}
- C12Y 305/04001: Cytosine deaminase (3.5.4.1)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2800/80: Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are systems, reagents, methods, and kits that are useful for the targeted editing of nucleic acids, including editing a single site within the genome of a cell or subject, e.g., within the human genome. In some embodiments, fusion proteins of Cas9 and cytosine deaminase domains, are provided. In some embodiments, methods for targeted nucleic acid editing are provided.

## Claims

### Claim 1

A polypeptide comprising a variant of a native cytosine deaminase (CD) domain, wherein the variant CD domain comprises a sequence at least 90% identical to amino acids 198-384 of SEQ ID NO: 48, and comprises P200A, N236A, P247K, Q318K, Q322K substitutions relative to SEQ ID NO: 48.

### Claim 2 (depends on 1)

The polypeptide of claim 1, further comprising a Y315F or a N244G substitution relative to SEQ ID NO: 48.

### Claim 3 (depends on 1)

The polypeptide of claim 1, further comprising H248N, K249L, H250L, G251C, F252G, L253F, and E254Y substitutions relative to SEQ ID NO: 48.

### Claim at position 4

4-9. (canceled)

### Claim 10 (depends on 1)

The polypeptide of claim 1, further comprising L234K, F310K, C243A, C321A, and C356A substitutions relative to SEQ ID NO: 48.

### Claim at position 6

11-13. (canceled)

### Claim 14 (depends on 1)

The polypeptide of claim 1, wherein the CD domain is a chimpanzee, gorilla, monkey, cow, dog, rat, mouse, or human APOBEC3G deaminase domain.

### Claim 15 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide further comprises a Cas9 domain that has nickase activity.

### Claim at position 9

16-20. (canceled)

### Claim 21 (depends on 15)

The polypeptide of claim 15, wherein the polypeptide further comprises a uracil glycosylase inhibitor (UGI) domain.

### Claim at position 11

22-23. (canceled)

### Claim 24 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide further comprises a nuclear localization sequence.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

A nucleic acid comprising a nucleotide sequence encoding the polypeptide of claim 1.

### Claim at position 15

27-32. (canceled)

### Claim 33 (depends on 26)

A host cell comprising the nucleic acid of claim 26.

### Claim at position 17

34-36. (canceled)

### Claim 37 (depends on 26)

A viral vector comprising the nucleic acid of claim 26.

### Claim at position 19

38-43. (canceled)

### Claim 44 (depends on 26)

A composition comprising the nucleic acid of claim 26 and a nucleic acid encoding a guide RNA.

### Claim at position 21

45-53. (canceled)

### Claim 54 (depends on 15)

A composition comprising the polypeptide of claim 15 and a guide RNA bound to the Cas9 domain of the polypeptide.

### Claim at position 23

55-57. (canceled)

### Claim 58 (depends on 15)

A method for targeted modification of a selected DNA sequence, the method comprising contacting the DNA sequence with a polypeptide of claim 15 and a nucleic acid comprising a guide RNA (gRNA) sequence targeted to the selected DNA sequence, where the gRNA complexed with the polypeptide and directs the polypeptide to the selected DNA sequence, wherein the targeted modification is the deamination of a deoxycytidine within the selected DNA sequence.

### Claim 59

(canceled)

### Claim 60 (depends on 58)

The method of claim 58, wherein the selected sequence comprises a CC motif.

### Claim 61 (depends on 60)

The method of claim 60, wherein the targeted modification is the deamination of the second deoxycytidine within the CC motif.

### Claim 62 (depends on 58)

The method of claim 58, wherein the selected sequence comprises a DCYD motif or a DCCYD motif, wherein D represent A, G, or T, and wherein Y denotes the T>C mutation.

### Claim 63

(canceled)

### Claim 64 (depends on 58)

The method of claim 58, wherein the selected sequence comprises a CCCA motif, wherein the targeted modification is the deamination of the third deoxycytidine within the motif.

### Claim at position 31

65-66. (canceled)

### Claim 67 (depends on 58)

The method of claim 58, wherein the contacting is in vivo in a subject identified as having a clinical condition, wherein the selected DNA sequence is associated with the clinical condition, and wherein the deamination corrects a point mutation in the selected DNA sequence associated with the clinical condition.

### Claim 68

(canceled)

### Claim 69 (depends on 67)

The method of claim 67, wherein the clinical condition is hereditary pyropoikilocytosis, cystic fibrosis, or holocarboxylase synthetase deficiency.

### Claim at position 35

70-72. (canceled)
